Impact of ocrelizumab on patient-reported fatigue and quality of life in relapsing multiple sclerosis patients treated for the first time with ocrelizumab (MoOzaRt): an observational study
Latest Information Update: 02 Apr 2024
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms NIS MoOzaRt
- Sponsors Roche
- 20 Dec 2023 Planned End Date changed from 28 Dec 2025 to 31 Mar 2026.
- 13 Oct 2023 Trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 13 Oct 2023 According to Trial design presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis, a first interim analysis of MoOzaRt will be presented, including 6- and 12-month-follow-up data of approximately 80-90 RMS patients. To date, 148 RMS patients have been recruited by 25 centres in Germany and Switzerland.